biotech

Image for Biotech Inventiva's 50% surge shows investor optimism over liver disease drugFinance

Biotech Inventiva's 50% surge shows investor optimism over liver disease drug

Image for Abivax CEO dismisses 'noise' around rumored Eli Lilly bidFinance

Abivax CEO dismisses 'noise' around rumored Eli Lilly bid

Image for France has had no request for investment approval in biotech Abivax - officialFinance

France has had no request for investment approval in biotech Abivax - official

Image for France denies contact with Eli Lilly over reported $17.5 billion Abivax dealFinance

France denies contact with Eli Lilly over reported $17.5 billion Abivax deal

Image for South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi

South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi

Date: December 16, 2025

Dec 16 (Reuters) - South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to develop and sell the biotech company's experimental...

Image for Pfizer completes up to $10 billion acquisition of Metsera

Pfizer completes up to $10 billion acquisition of Metsera

Date: November 13, 2025

(Reuters) -Metsera shareholders on Thursday approved Pfizer's takeover offer worth up to $10 billion, allowing the U.S. pharmaceutical giant re-entry into the lucrative obesity treatment market after...

Image for BioNTech lifts 2025 revenue guidance on BMS partnership payment

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Date: November 3, 2025

FRANKFURT (Reuters) -Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol Myers Squibb in a cancer immunotherapy alliance that...

Image for Novartis CEO defends $12 billion deal for Avidity as 'appropriate risk to take'

Novartis CEO defends $12 billion deal for Avidity as 'appropriate risk to take'

Date: October 27, 2025

LONDON (Reuters) -Shares of Novartis fell 1% on Monday following news of the company's plans to acquire U.S. biotech Avidity Biosciences for about $12 billion, marking the Swiss drugmaker's largest...

Image for Genmab to buy Dutch cancer drugmaker Merus for $8 billion

Genmab to buy Dutch cancer drugmaker Merus for $8 billion

Date: September 29, 2025

OSLO (Reuters) -Denmark's Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, for $8 billion in cash, the two companies said in a...

Image for Novartis weighs deal for biotech Avidity Biosciences, FT reports

Novartis weighs deal for biotech Avidity Biosciences, FT reports

Date: August 6, 2025

(Corrects typo in paragraph 1) (Reuters) -Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported, citing people familiar...